A recent study showed that tumors with increased PD-L1 and CD8 expression were associated with better survival based on the evaluation of the tumor immune microenvironment of CRC using the IHC data of PD-L1, PD-1, and CD8 [31]. This evidence concerns the gene PDCD1 and colorectal carcinoma.